A sudden, mechanical head injury that disrupts brain function is termed traumatic brain injury (TBI). Motor vehicle accidents, violence, and falls are the most common causes of TBI. Symptoms such as headache, fatigue, and mood changes can occur across TBI severities. However, in moderate to severe TBI these symptoms may be compounded by progressively worsening headaches, inability to awaken from sleep, agitation, and seizures, among others. Disabilities resulting from TBI depend on the extent of brain damage—cognition deficits and mental health problems are common; in the extreme, severe TBI patients may be in a vegetative state. With no neuroprotective therapies currently available, the treatment goal in TBI is to prevent further brain damage. Surgery may be required for brain hematomas or contusions, and moderate to severe cases require rehabilitation tailored to patients' specific TBI manifestations.

Questions Answered:

  • The number of diagnosed TBI events will increase slightly over the 2014-2024 forecast period. What is the number of diagnosed TBI events in the United States and the five major European markets (France, Germany, Italy, Spain, and the United Kingdom)? How will the number of diagnosed TBI events change over the ten-year forecast period? How many diagnosed TBI events are classified mild, moderate, or severe at this time and through 2024?
  • Research into the pathophysiological basis of TBI has revealed various, complicated signaling cascades. What new insights are informing experts’ understanding of TBI? What are the key avenues of TBI preclinical and clinical research and drug development efforts?
  • Unmet needs in TBI span a range of challenging issues. What are the emerging TBI therapies in late-stage development and to what degree could they address the unmet need in TBI? What are the key primary and secondary clinical end points on which new therapies are evaluated and how do interviewed experts perceive these end points?

Scope:

Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.

Primary research: Eight country-specific interviews with thought-leading neurologists.

Epidemiology: Total diagnosed events of TBI, diagnosed events of TBI by severity, by gender, and by treatment setting.

Emerging therapies: Phase III: 1; Phase II: 5; coverage of select preclinical and Phase I products.

Table of contents

  • Traumatic Brain Injury - Landscape & Forecast - Disease Landscape & Forecast
    • Executive Summary
      • Introduction
        • Key Parameters of the Traumatic Brain Injury Landscape, 2014-2024
        • Actionable Recommendations for Drug Developers
      • Note About Our Epidemiology Estimates
      • Commercial Outlook
        • Market Outlook
          • Key Parameters of the Traumatic Brain Injury Landscape, 2014-2024
          • Traumatic Brain Injury Landscape, 2014-2024
        • Drivers and Constraints
          • Drivers of Growth
          • Constraints on Growth
      • Etiology and Pathophysiology
        • Disease Overview
          • Typical Traumatic Brain Injuries
            • Expert Insight on Typical Traumatic Brain Injuries
          • The Etiology of Traumatic Brain Injury
            • Expert Insight on the Etiology of Traumatic Brain Injury
          • The Pathophysiology of Traumatic Brain Injury
            • Expert Insight on the Pathophysiology of Traumatic Brain Injury
          • The Glasgow Coma Scale
            • Expert Insight on Use of the Glasgow Coma Scale
          • Symptoms of Traumatic Brain Injury
            • Common Symptoms of Traumatic Brain Injury
          • Biomarkers for Traumatic Brain Injury
            • Expert Insight on Biomarkers for Traumatic Brain Injury
        • Epidemiology Overview
          • Introduction
            • Disease Definition
            • Key Sources for Traumatic Brain Injury Epidemiology and Model Parameters
            • Risk/Protective Factors for Traumatic Brain Injury
          • Epidemiology Populations
            • Number of Diagnosed Events of Traumatic Brain Injury, 2014-2024 (thousands)
            • Literature Review
            • Age Distribution of U.S. Diagnosed Traumatic Brain Injury Events, 2014
            • Age Distribution of Diagnosed Traumatic Brain Injury Events in the Major European Markets, 2014
            • Studies Included in the Analysis of Traumatic Brain Injury
            • Number of Diagnosed Events of Traumatic Brain Injury, by Gender, 2014-2024 (thousands)
            • Studies Excluded in the Analysis of Traumatic Bain Injury
            • Number of Diagnosed Events of Traumatic Brain Injury by Treatment Setting, 2014-2024 (thousands)
            • Populations and Forecast Parameters
            • Traumatic Brain Injury Populations and Foercast Parameters
            • Population Methods
            • Inpatient Setting
            • Outpatient Setting
            • Traumatic Brain Injury Severity
            • Note About Our Epidemiology Estimates
        • Current Treatment Overview
          • Diagnosis
            • Diagnostic Tools
            • Triage and Transport
            • Treatment Providers
            • Expert Insight on Commonly Used Diagnostic Tools for Traumatic Brain Injury
          • Treatment Goals
            • Expert Insight on Treatment Goals in Traumatic Brain Injury
            • Trial End Points
            • Key Clinical Trial End Points
            • Expert Insight on Key Clinical Trial End Points
          • Key Current Therapies
            • Key Current Traumatic Brain Injury Therapies Used in the Acute Setting
            • Key Current Traumatic Brain Injury Therapies Used During Rehabilitation
            • Use of Key Current Therapies
            • Expert Insight on Use of Key Current Therapies
            • Hyperbaric Oxygen Therapy
            • Expert Insight on Hyperbaric Oxygen Therapy
            • Hypothermia
            • Expert Insight on Hypothermia
          • Medical Practice
            • Treatment Algorithm of Traumatic Brain Injury
            • Treatment Algorithm of Traumatic Brain Injury
        • Unmet Need Overview
          • Introduction
            • Unmet Needs for Traumatic Brain Injury
            • Unmet Needs for Traumatic Brain Injury
            • Expert Insight on Unmet Needs for Traumatic Brain Injury
        • Emerging Therapies Overview
          • Introduction
            • Emerging Pharmcological Therapies for Traumatic Brain Injury
            • Emerging Treatments for Traumatic Brain Injury
          • Patient Registries for Trauma
            • Select Patient Registries for Trauma
          • Orphan-Drug Designation
            • Orphan-Drug Designation for Traumatic Brain Injury Therapies
            • Orphan-Drug Provisions—United States
            • Orphan-Drug Provisions—Europe
          • Key Emerging Therapies
            • Overview
            • Ongoing Clinical Trials for Tranexamic Acid
            • Outlook
            • Ongoing Clinical Trials for Cyclosporin A
            • Expert Insight on Cyclosporin A
            • Overview
            • Ongoing Clinical Trials for Trofinetide
            • Expert Insight on Trofinetide
            • Expert Insight on VAS-203
            • Ongoing Clinical Trials for Glyburide
            • Ongoing Clinical Trials for Botulinum Toxin A
            • Expert Insight on Progesterone
            • Select Therapies in Early-Stage Development
            • Expert Insight on Select Therapies in Early-Stage Development
        • Access and Reimbursement Overview
          • Region-Specific Reimbursement Practices
          • Appendix
            • Experts Interviewed
            • Traumatic Brain Injury Bibliography

        Author(s): Jing Wu

        Jing is a Principal business insights analyst in the infectious, niche, and rare diseases team at Decision Resources Group, focusing on a diverse set of key niche and rare diseases.

        Jing completed her M.B.A. at Boston University with concentrations in health sector management and finance. She also holds an M.S. in biomedical science from the University of Massachusetts Medical School and a B.S. in biochemistry from Nanjing University in China. She worked as a research assistant at the Molecular Cardiology Research Institute of Tufts Medical Center, where she was involved in several projects to identify genetic regulators contributing to heart diseases.


        Related Reports

        Traumatic Brain Injury - Epidemiology - Mature Markets

        DRG Epidemiology's coverage of traumatic brain injury (TBI) comprises epidemiological estimates of...

        View Details

        Traumatic Brain Injury - Executive Insights - Executive Insights (US)

        TBI is a major cause of death and disability in the United States; DRG Epidemiology estimates that there were 250,000 moderate to severe TBI events diagnosed in U.S. hospitals / emergency rooms in...

        View Details